The assessment of stroke and bleeding risk in atrial fibrillation: Where are we now?

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 12, 2010, Pages 1703-1710

  Pamukcu, Burak ^a   Lane, Deirdre A ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

atrial fibrillation; bleeding risk; oral anticoagulants; stroke risk stratification

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; NONSTEROID ANTIINFLAMMATORY AGENT; WARFARIN;

AGE; ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MITRAL VALVE STENOSIS; PRESCRIPTION; REVIEW; STROKE; VASCULAR DISEASE;

AGING; ATRIAL FIBRILLATION; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SOCIETIES, MEDICAL; STROKE; THROMBOEMBOLISM;

EID: 78649664205     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.153     Document Type: Review

References (47)

1. Lip GY, Golding DJ, Nazir M, Beevers DG, Child DL, Fletcher RI. A survey of atrial fbrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br. J. Gen. Pract. 47, 285-289 (1997).
2. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fbrillation: population-based estimates. Am. J. Cardiol. 82(8A), 2N-9N (1998). (Pubitemid 28507114)
3. Atrial Fibrillation Investigators. Risk factors for stroke and effcacy of antithrombotic therapy in atrial fbrillation: analysis of pooled data from fve randomized controlled trials. Arch. Intern. Med. 154, 1449-1457 (1994).
4. Wolf PA, Abbott RD, Kannel WB. Atrial fbrillation: a major contributor to stroke in the elderly; the Framingham Heart Study. Arch. Intern. Med. 147, 1561-1564 (1987).
5. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fbrillation in a population based cohort. The Framingham Heart Study. JAMA 271, 840-844 (1994).
6. Petty GW, Khandheria BK, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Predictors of cerebrovascular events and death among patients with valvular heart disease: a population-based study. Stroke 31, 2628-2635 (2000).
7. Fuster V, Rydén LE, Cannom DS et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Circulation 114, e257-e354 (2006).
8. Singer DE, Albers GW, Dalen JE et al.; American College of Chest Physicians. Antithrombotic therapy in atrial fbrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines 8th edition. Chest 133, 546S-592S (2008).
9. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fbrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA); Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart. J. 31(19), 2369-2429 (2010).
10. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classifcation schemes for predicting stroke: results of the National Registry of Atrial Fibrillation. JAMA 285, 2864-2870 (2001).
11. Wang TJ, Massaro JM, Levy D et al. A risk score for predicting stroke or death in individuals with new onset atrial fbrillation in the community: the Framingham Heart Study. JAMA 290, 1049-1056 (2003).
12. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW Factors associated with ischemic stroke during aspirin therapy in atrial fbrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) investigators. Stroke 30, 1223-1229 (1999).
13. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratifcation schemes to predict stroke in patients with non-valvular atrial fbrillation. Stroke 39, 1901-1910 (2008).
14. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Stroke risk in atrial fbrillation patients on warfarin. Predictive ability of risk stratifcation schemes for primary and secondary prevention. Thromb. Haemost. 101, 367-372 (2009).
15. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refning clinical risk stratifcation for predicting stroke and thromboembolism in atrial fbrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest 137, 263-272 (2010).
16. Lip GYH, Halperin JL. Improving stroke risk stratifcation in atrial fbrillation. Am. J. Med. 123, 484-488 (2010).
17. Pisters R, van Oostenbrugge RJ, Knottnerus IL et al. The likelihood of decreasing strokes in atrial fbrillation patients by strict application of guidelines. Europace 12, 779-784 (2010).
18. Devereaux PJ, Anderson DR, Gardner MJ et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fbrillation: observational study. Br. Med. J. 323, 1218-1222 (2001).
19. Connolly SJ, Pogue J, Hart RG et al.; ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fbrillation. N. Engl. J. Med. 360, 2066-2078 (2009).
20. Hylek EM, D'Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fbrillation. Stroke 37, 1075-1080 (2006).
21. Devereaux PJ, Ghali WA, Gibson NE et al. Physicians' recommendations for patients who undergo noncardiac surgery. Clin. Invest. Med. 23, 116-123 (2000).
22. Abdelhafz AH, Wheeldon NM. Results of an open-label, prospective study of anticoagulant therapy for atrial fbrillation in an outpatient anticoagulation clinic. Clin. Ther. 26, 1470-1478 (2004).
23. Wehinger C, Stöllberger C, Länger T, Schneider B, Finsterer J. Evaluation of risk factors for stroke/embolism and of complications due to anticoagulant therapy in atrial fbrillation. Stroke 32, 2246-2252 (2001).
24. Hughes M, Lip GYH; Guideline Development Group for the NICE national clinical guideline for management of atrial fbrillation in primary and secondary care. Risk factors for anticoagulation-related bleeding complications in patients with atrial fbrillation: a systematic review. QJM 100, 599-607 (2007).
25. Fang MC, Go AS, Chang Y et al. Death and disability from warfarin-associated intracranial and extracranial haemorrhages. Am. J. Med. 120, 700-705 (2007).
26. Kuijer PMM, Hutten BA, Prins MH, Buller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch. Intern. Med. 159, 457-460 (1999).
27. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am. J. Med. 105, 91-99 (1998).
28. Gage BF, Yan Y, Milligan PE et al. Clinical classifcation schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am. Heart J. 151, 713-719 (2006).
29. Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 130, 1390-1396 (2006).
30. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fbrillation patients: the Euro Heart Survey. Chest DOI: 10.1378/chest.10-0134 (2010) (Epub ahead of print).
31. Zhu Y, Shennan M, Reynolds KK et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin. Chem. 53, 1199-1205 (2007).
32. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientifc, and clinical issues. J. Thromb. Thrombolysis 25, 45-51 (2008).
33. Anderson JL, Horne BD, Stevens SM et al.; Couma-Gen Investigators. Randomized trial of genotype guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116, 2563-2570 (2007).
34. Leey JA, McCabe S, Koch JA, Miles TP. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fbrillation. Am. J. Geriatr. Pharmacother. 7, 197-203 (2009).
35. Nieuwlaat R, Barker L, Kim YK et al. Underuse of evidence-based warfarin dosing methods for atrial fbrillation patients. Thromb. Res. 125, e128-e131 (2010).
36. Wan Y, Heneghan C, Perera R et al. Anticoagulation control and prediction of adverse events in patients with atrial fbrillation: a systematic review. Circ. Cardiovasc. Qual. Outcomes 1, 84-91 (2008).
37. Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fbrillation: observing outcomes associated with varying levels of INR control. Thromb. Res. 124, 37-41 (2009).
38. Connolly SJ, Ezekowitz MD, Yusuf S et al. and the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fbrillation. N. Engl. J. Med. 361, 1139-1151 (2009).
39. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N. Engl. J. Med. 347, 969-974 (2002).
40. Eikelboom JW, O'Donnell M, Yusuf S et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fbrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am. Heart J. 159, 348-353 (2010).
41. ROCKET AF Study Investigators. Rivaroxaban-Once Daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am. Heart J. 159, 340-347 (2010).
42. Ostermayer SH, Reisman M, Kramer PH et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fbrillation: results from the international multi-center feasibility trials. J. Am. Coll. Cardiol. 46, 9-14 (2005).
43. Block PC, Burstein S, Casale PN et al Percutaneous left atrial appendage occlusion for patients in atrial fbrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. JA CC Cardiovasc. Interv. 2, 594-600 (2009).
44. Holmes DR, Reddy VY, Turi ZG et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fbrillation: a randomised non-inferiority trial. Lancet 374(9689), 534-542 (2009).
45. Connolly SJ, Crijns HJ, Torp-Pedersen C et al. ATHENA Investigators. Analysis of stroke in ATHENA: a Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Effcacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in Patients with Atrial Fibrillation/Atrial Flutter. Circulation 120, 1174-1180 (2009).
46. Tzou WS, Marchlinski FE, Zado ES et al Long-term outcome after successful catheter ablation of atrial fbrillation. Circ. Arrhythm. Electrophysiol. 3, 237-242 (2010).
47. Rietbrock S, Heeley E, Plumb J, van Staa T Chronic atrial fbrillation: incidence, prevalence, and prediction of stroke using the congestive heart failure, hypertension, age <75, diabetes mellitus, and prior stroke or transient ischemic attack (CHADS) risk stratifcation scheme. Am. Heart J. 156, 57-64 (2008).